(1R,2S)-2-benzyloxycarbonylaminocyclobutane-1-carboxylic acid | 221158-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S)-2-benzyloxycarbonylaminocyclobutane-1-carboxylic acid
• 英文别名: cis-2-Benzyloxycarbonylaminocyclobutane-carboxylic acid；(1R,2S)-2-(phenylmethoxycarbonylamino)cyclobutane-1-carboxylic acid
• CAS: 221158-93-6
• 化学式: C₁₃H₁₅NO₄
• 分子量: 249.266
• InChiKey: ZNRUEEQIUVKKBL-MNOVXSKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,2S)-2-benzyloxycarbonylaminocyclobutane-1-carboxylic acid 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 以80%的产率得到(1S,5R)-benzyl 3-oxo-2,4-diazabicyclo[3.2.0]heptane-2-carboxylate
  参考文献：
  名称：

  Synthesis and structural features of cyclobutane-containing chiral bicyclic ureas

  摘要：

  Efficient and stereoselective synthetic routes have been developed for the preparation of chiral N-mono-protected cyclobutane bicyclic ureas in which one of the NH groups is protected as a benzyl or tert-butyl carbamate. Ureas in both enantiomeric forms were obtained from a common chiral precursor via the selective manipulation of functional groups. These compounds have been subjected to a structural study in solution and in the solid state. NMR, IR and TEM techniques evidence a strong tendency to aggregation in solution giving regular assemblies, which is a result of intermolecular urea N-H center dot center dot center dot O=C hydrogen bonding. In the solid state, X-ray analysis shows that two urea molecules interact through only one hydrogen bond yielding infinite chains. This fact and the almost complete coplanarity of both the urea and the carbamate carbonyl groups determine the crystal packing to be formed by a parallel molecular arrangement. All these structural features are well supported by theoretical calculations that allow us to conclude that the formation of a network based on hydrogen bonding is energetically favourable. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2010.01.020
• 作为产物：
  描述：

  methyl 2-benzyloxycarbonylamino-(1R,2S)-cyclobutane-1-carboxylate 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 (1R,2S)-2-benzyloxycarbonylaminocyclobutane-1-carboxylic acid
  参考文献：
  名称：

  Stereoselective synthesis of (−)-(1R,2S)-2-aminocyclobutane-1-carboxylic acid, a conformationally constrained β-amino acid

  摘要：

  The title compound as well as some derivatives have been synthesized for the first time in optically active form by means of a chemoenzymatic transformation used to induce asymmetry in achiral precursors. The enantio- and diastereomeric purity has been determined by HPLC and NMR techniques. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00462-5

文献信息

• Designing hybrid foldamers: the effect on the peptide conformational bias of β- versus α- and γ-linear residues in alternation with (1R,2S)-2-aminocyclobutane-1-carboxylic acid
  作者：Sergio Celis、Esther Gorrea、Pau Nolis、Ona Illa、Rosa M. Ortuño

  DOI：10.1039/c1ob06575k

  日期：——

  Several oligomers constructed with (1R,2S)-2-aminocyclobutane-1-carboxylic acid and glycine, β-alanine, and γ-amino butyric acid (GABA), respectively, joined in alternation have been synthesized and studied by means of NMR and CD experiments as well as with computational calculations. Results account for the spacer length effect on folding and show that conformational preference for these hybrid peptides can be tuned from β-sheet-like folding for those containing a C2 or C4 linear segment to a helical folding for those with a C3 spacer between cyclobutane residues. The introduction of cyclic spacers between these residues does not modify the extended ribbon-type structure previously manifested in poly(cis-cyclobutane) β-oligomers.

  用(1R,2S)-2-氨基环丁烷-1-羧酸、甘氨酸、β-丙氨酸和γ-氨基丁酸分别交替连接而成的几种寡聚体，已通过NMR和CD实验以及计算模拟进行了合成和研究。结果解释了间隔长度对折叠的影响，并表明这些杂合肽的构象偏好可以从含有C2或C4线性段的对β片层样折叠调节为含有C3间隔的环丁烷残基之间的螺旋折叠。在这些残基之间引入环形间隔不会改变之前在多(顺式-环丁烷)β-寡聚体中展现的扩展带状结构。
• [EN] AMINO QUINOLINE DERIVATIVES INHIBITORS OF HCV<br/>[FR] DÉRIVÉS D'AMINO-QUINOLÉINE INHIBITEURS DE VHC
  申请人：GILEAD SCIENCES INC

  公开号：WO2013090929A1

  公开（公告）日：2013-06-20

  A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are defined herein, and methods of treating HCV infection in a patient are disclosed.

  一种化合物的化学式I：或其药用可接受的盐，其中取代基在此定义，并公开了治疗患者HCV感染的方法。
• [EN] TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS<br/>[FR] INHIBITEURS DE SÉCRÉTION DE PROTÉINE À BASE DE TRIAZACYCLODODÉCANSULFONAMIDE ("TCD")
  申请人：KEZAR LIFE SCIENCES

  公开号：WO2019178510A1

  公开（公告）日：2019-09-19

  Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

  本文提供了基于三氮杂环十二烷磺酰胺（"TCD"）的蛋白质分泌抑制剂，例如Sec61的抑制剂，其制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了符合Formula（I）的化合物及其药用盐和包括它们的组合物。本文披露的化合物可以用于治疗炎症和/或癌症等疾病。
• [EN] PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QUE MODULATEURS D'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009015166A1

  公开（公告）日：2009-01-29

  The present application describes modulators of MIP-1 of formula (I) : or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

  本申请描述了公式（I）的MIP-1调节剂：或其立体异构体或药用可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。